RT @ibrahimazaronc: Now that TDxd is FDA approved for HER2 mutant NSCLC, it's a good time to read our review on the topic https://t.co/n0…
Now that TDxd is FDA approved for HER2 mutant NSCLC, it's a good time to read our review on the topic https://t.co/n0Miab0KS1
Spotlight on Trastuzumab Deruxtecan (DS-8201,T-DXd) for HER2 Mutation Positive Non-Small Cell Lung Cancer https://t.co/spKv7vCGvl
Spotlight on Trastuzumab Deruxtecan (DS-8201,T-DXd) for HER2 Mutation Positive Non-Small Cell Lung Cancer https://t.co/spKv7vCGvl
Spotlight on Trastuzumab Deruxtecan (DS-8201,T-DXd) for HER2 Mutation Positive Non-Small Cell Lung Cancer https://t.co/spKv7vCGvl
Check out or recent publication on Trastuzumab Deruxtecan in HER mutated NSCLC https://t.co/fcvKsUVDIp Thank you @MNagasaka @ibrahimazaronc for all the help and guidance!! #MedTwitter #oncology #lungcancer
RT @ibrahimazaronc: With the recent publication of the results of DESTINY-Lung01 in NEJM, we are excited to share a timely review on everyt…
RT @ibrahimazaronc: With the recent publication of the results of DESTINY-Lung01 in NEJM, we are excited to share a timely review on everyt…
Great job, especially @ibrahimazaronc and @AlkassisSamer !!
With the recent publication of the results of DESTINY-Lung01 in NEJM, we are excited to share a timely review on everything you need to know about Trastuzumab Deruxtecan in HER2 mutation + NSCLC @MNagasaka @AlkassisSamer @faresalsawah @NajeebAl_Hallak